{
  "ticker": "EYE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973651",
  "id": "02973651",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250729",
  "time": "0847",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7nkxf3dc881.pdf",
  "summary": "### **Material Information Summary \u2013 Nova Eye Medical Limited (ASX: EYE) \u2013 Quarterly Report (June 2025)**  \n\n#### **Financial & Operational Highlights**  \n- **FY25 Revenue**: Record **A$29.2M** (US$18.8M), up **23% YoY** (constant currency).  \n- **H2 FY25 EBITDA**: Glaucoma segment turned **positive** (US$65K), group EBITDA loss **reduced by US$2.1M** vs. H1.  \n- **Cash Position**: **A$5.1M** at 30 June 2025; Q4 operational cash outflow **A$847K** (improving trend).  \n\n#### **Guidance for FY26**  \n- **Revenue Forecast**: **US$21M\u2013US$24M** (A$32M\u2013A$37M), excluding China.  \n- **Profitability Target**: **Breakeven EBITDA in H1 FY26**, continued cashflow improvement.  \n\n#### **Strategic Updates**  \n- **USA Reimbursement**: Proposed Medicare rates for 2026 (finalized Nov 2025) likely to support demand for glaucoma products.  \n- **Market Growth**: Independent survey projects US MIGS market share to rise from **2.4% to 3.4%** by June 2026.  \n- **China Approval**: **iTrack\u2122 Advance regulatory approval expected late 2025**; current sales continue.  \n\n#### **Other Material Developments**  \n- **Government Grant**: **A$488K** awarded for eye disease detection tech (quantum/biomedical collaboration).  \n\n---  \n**Omitted**: Routine operational updates, director details, and non-material milestones.  \n**Source**: ASX announcement dated 29 July 2025.",
  "usage": {
    "prompt_tokens": 4673,
    "completion_tokens": 376,
    "total_tokens": 5049,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T22:57:33.642255"
}